NEWS:
Press Releases
Industry Articles
 
FINANCIALS:
Equation Info
Annual Reports
Quarterly Releases
SEC Filings
Stock Status
 
COMPANY INFO:
Corporate Profile
Presentations
Governance
IR Contacts
Request Investor Info.

EP MedSystems Reports Second Quarter Financial Results

WEST BERLIN, N.J.--(BUSINESS WIRE)--Aug. 15, 2006--EP MedSystems, Inc. (NASDAQ: EPMD - News), a market leader in electrophysiology products used to diagnose and treat certain types of cardiac rhythm disorders, today announced financial results for the three and six months ended June 30, 2006. For the six months ended June 30, 2006, revenues were $7,390,000, a decrease of 10% from the $8,231,000 reported in the same period last year. Sales of our consumable products were up 2% in the first six months of 2006 over the same six months of 2005 primarily as a result of a 31% increase in sales of ViewFlexÔ ultrasound catheters. The gross margin percentage for the six months ended June 30, 2006 remained flat compared to the comparable period of 2005. The net loss for the six months ended June 30, 2006 was $3,708,000 or ($0.13) per share, compared to $2,573,000 or ($0.10) per share in the prior year.

 The Company finished the quarter with cash and cash equivalents of $11,409,000.

 Revenues for the quarter were $3,312,000, a decrease of 30% from the $4,755,000 reported for the three months ended June 30, 2005. Sales of our consumable products were up 18% in the second quarter of 2006 over the same quarter in 2005 primarily as a result of a 37% increase in sales of our ViewFlexÔ ultrasound catheters. The gross margin for the three months ended June 30, 2006 was flat compared to the same period in 2005. The net loss for the quarter was $2,213,000, compared to the $1,166,000 reported in 2005. The basic and diluted loss per share for the three months ended June 30, 2006 was ($0.07), which compared to ($0.05) for the comparable period in 2005.


Included in the second quarter’s loss was an accrual of $345,000 which reflects management’s estimate of a fine to be levied by the U.S. Department of Commerce for export violations. The Company has had an ongoing investigation by the United States government concerning these violations for quite some time.

 David Jenkins, EP MedSystems’ Chairman, President and Chief Executive Officer commented, “We are disappointed in the second quarter sales results and are taking steps to address this through our search for a new CEO with a strong sales and marketing background.  In addition, we have made good progress in resolving investigations by federal government agencies concerning export violations and hope to fully resolve these matters shortly.  We believe that both of these steps will allow us to focus on operational execution in the quarters ahead.”


Corporate Conference Call
EP MedSystems' management will host a conference call today, August 15, 2006, at 10:00 a.m. EST to review the second quarter financial results and other corporate events. David Jenkins, Chairman, President and Chief Executive Officer, will host the call and take part in a Q & A session.

The call can be accessed by dialing (800) 240-4186 and giving the company name, "EP MedSystems". Participants are asked to call the number approximately 10 minutes before the conference call begins. A replay of the conference call will be available two hours after the call for the following five days by dialing (800) 405-2236 and entering the following pass code: 11067822 #.

The call can also be accessed live on the web at www.epmedsystems.com in the investor relations area of the site or by going to http://www.mkr-group.com.


About EP MedSystems:
EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac rhythm disorders. The Company's EP product line includes the EP-WorkMate® Electrophysiology Workstation with RPM(TM) Real-time Position Management(TM) navigation technology, the EP-4(TM) Computerized Cardiac Stimulator, fixed and deflectable diagnostic electrophysiology catheters and related disposable supplies, the ALERT® System and ALERT family of internal cardioversion catheters, and the ViewMate® intracardiac ultrasound catheter imaging. For more information, visit our Website at www.epmedsystems.com.

Forward Looking Statements:
This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Forward-looking statements include information concerning our possible or assumed future results of operations and statements preceded by, followed by or including the words "believes", "expects", "anticipates", "intends", "plans", "estimates", or similar expressions. Such forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of market acceptance of our products and level of sales, uncertainty of future profitability and future liquidity needs; possible fines costs or penalties that may be incurred in connection with the government inquires and investigations and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual Report filed on Form 10-K and quarterly reports filed on Form 10-Q.

EP MedSystems cautions investors and others to review the cautionary statements set forth in this press release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on this press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.


###

 

Other highlights reported for the quarter and six months include:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

 

 

2006

 

2005

 

2006

 

2005

Net Sales

 

$3,312,000

 

$4,755,000

 

$7,390,000

 

$8,231,000

Cost of products sold

 

1,244,000

 

1,750,000

 

2,832,000

 

3,028,000

Gross Profit

 

2,068,000

 

3,005,000

 

4,558,000

 

5,203,000

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

Sales and marketing

 

2,556,000

 

2,174,000

 

4,970,000

 

4,303,000

General and administrative

 

1,093,000

 

1,389,000

 

1,957,000

 

2,260,000

Research and development

 

681,000

 

589,000

 

1,379,000

 

1,173,000

Total Operating Expenses

 

4,330,000

 

4,152,000

 

8,306,000

 

7,736,000

Loss from operations

 

(2,262,000)

 

(1,147,000)

 

(3,748,000)

 

(2,533,000)

 

 

 

 

 

 

 

 

 

Interest income (expense)

 

49,000

 

(19,000)

 

40,000

 

(40,000)

 

 

 

 

 

 

 

 

 

Net Loss

 

$(2,213,000)

 

$(1,166,000)

 

$(3,708,000)

 

$(2,573,000)

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share

 

$(0.07)

 

$(0.05)

 

$(0.13)

 

$(0.10)

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

30,365,236

 

25,814,176

 

28,277,500

 

25,709,053





 

Balance Sheet Data

 

At June 30, 2006

 

At June 30, 2005

Cash and cash equivalents

$11,409,000

 

$7,716,000

$7,716,000

Working capital

 

14,150,000

 

10,608,000

Total assets

 

21,082,000

 

18,020,000

Total liabilities

 

6,496,000

 

7,041,000

Shareholders equity

 

14,586,000

 

10,979,000



For Further Information Contact:

Matthew C. Hill, Chief Financial Officer
(856) 753-8533

MKR Group, LLC
Charles Messman, Todd Kehrli
(818)556-3700